How to Consider GLP-1 Receptor Agonists in Bipolar Disorder and CKD
How should clinicians use this study when considering GLP-1 receptor agonists for adults with bipolar disorder and chronic kidney disease?
Adults with bipolar disorder and chronic kidney disease have high cardiorenal risk and may also be exposed to nephrotoxic psychotropics such as lithium. This article does not establish a treatment recommendation, but it does offer a clinically useful framework for identifying when the observed kidney replacement therapy signal should prompt multidisciplinary discussion rather than be ignored.
-
Confirm the population matches the study
Apply these findings only to adults 18 years or older with bipolar disorder and mild-to-moderate chronic kidney disease, defined in the study as CKD stage 3 or less. The article evaluated new users of GLP-1 receptor agonists in patients with documented bipolar disorder and CKD and excluded individuals with documented dialysis or kidney transplant before baseline.
-
Use the renal signal, not the utilization signal, to frame the discussion
Center the conversation on kidney replacement therapy risk, because that was the most consistent finding across analyses. Compared with DPP-4 inhibitor users, GLP-1 receptor agonist use was associated with lower observed risk of kidney replacement therapy with an adjusted hazard ratio of 0.56, and the association was also seen versus RAAS inhibitors with an adjusted hazard ratio of 0.66, whereas health care utilization findings were less stable after propensity-matched survival analyses.
-
Interpret the findings as associative rather than prescriptive
Present the result as a hypothesis-generating association, not proof that GLP-1 receptor agonists prevent kidney failure in bipolar disorder. The authors explicitly state that the present findings alone do not establish a basis for treatment recommendations and that prospective replication and randomized trials are needed.
-
Prioritize patients who already have a clinical reason to receive a GLP-1 receptor agonist
The article is most clinically relevant when a patient with bipolar disorder and CKD is already a candidate for a GLP-1 receptor agonist because of diabetes, obesity, or related metabolic indications. The study emphasizes that GLP-1 receptor agonists are increasingly used in these medically complex settings and suggests that renal risk deserves consideration alongside those existing indications.
-
Do not exclude patients solely because of psychotropic background
The observed kidney replacement therapy association remained significant across several concurrent psychotropic regimens, including antipsychotics, lithium, valproate, and lamotrigine. In subgroup analyses, the adjusted hazard ratio for kidney replacement therapy was 0.41 in the lithium subgroup, 0.53 with antipsychotics, 0.65 with valproate, and 0.57 with lamotrigine, which supports considering the signal across common bipolar treatment backgrounds.
-
Use subgroup findings to support generalizability, not to rank candidates
The observed kidney replacement therapy association was consistent across sex, race, and obesity status, with directionally similar but nonsignificant findings in Hispanic individuals. Use this to avoid dismissing the signal in nonobese patients or in those on lithium, but do not use subgroup hazard ratios to claim that one subgroup should preferentially receive treatment.
-
Discuss the strongest absolute risk estimates available
If you need a concrete way to explain the size of the observed renal difference, use the propensity-matched results rather than only the adjusted hazard ratios. After matching against DPP-4 inhibitor users, 5-year event-free survival for kidney replacement therapy was 87.93% with GLP-1 receptor agonists versus 84.63%, and in the matched comparison with RAAS inhibitors the absolute reduction was 4.91 percentage points with a number needed to treat of 21.
-
Coordinate psychiatry, nephrology, and endocrinology input
Use the finding to prompt collaborative care rather than a stand-alone psychiatric prescribing decision. The article specifically suggests closer collaboration between psychiatry, nephrology, and endocrinology as a useful clinical response while the association is being further evaluated.
Clinical Considerations
- This was a retrospective observational TriNetX study, so residual confounding by indication, disease severity, lifestyle factors, psychiatric illness severity, treatment engagement, and social determinants of health cannot be excluded.
- The article states that its findings do not establish causality or provide a basis for treatment recommendations.
- CKD and kidney replacement therapy were identified with diagnosis and procedure codes rather than laboratory confirmation or registry linkage, so misclassification is possible.
- Known GLP-1 receptor agonist-associated lithium toxicity risks still warrant prospective safety monitoring in lithium-treated patients.
Bottom Line
In adults with bipolar disorder and chronic kidney disease who are already candidates for GLP-1 receptor agonists, use this study to elevate renal risk in multidisciplinary treatment discussions, but not to justify kidney-protection prescribing on its own.
